Healthcare
Latest Healthcare Analysis
View More
Billion-Dollar Market Potential for Targeted Cancer Therapies
Radiopharmaceuticals are revolutionizing cancer treatment, attracting billions in investments. Discover the potential and challenges for investors...
Roche Shares Tumble After Obesity Drug Data
Roche's stock dropped 4.5% due to gastrointestinal side effects from its obesity drug CT-388, raising concerns among investors about the drug's...
Integra LifeSciences Implements Quality Compliance Plan
Integra LifeSciences' commitment to quality compliance and supply chain resilience may yield growth opportunities for retail investors' portfolios.
Palantir, Dell, and Erie Indemnity to Join S&P 500
Major shifts in the S&P 500, MidCap 400, and SmallCap 600 include Palantir, Dell, and Erie Indemnity.
Top Picks
View More
Top Growth Stocks Q2 2022
Growth investing tends to be a medium to long-term investing strategy. Investors looking for growth stocks seek companies that appear to have a...
Top Growth Stocks Q1 2022
Growth investing tends to be a medium to long term investing strategy. Investors looking for growth stocks seek companies that appear to have a...
Top Momentum Stocks Q1 2022
Momentum investing tends to be a short-term investing strategy. Investors looking to buy shares in a stock look for signs of upward momentum and...
Q4 2021 Top Healthcare stocks to consider
Healthcare can be a lucrative investment area, but it's also a challenging sector to invest in. Here are some top health stocks in momentum, growth...
Press Releases
View MoreCardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx™ for Recurrent Pericarditis
Toronto, ON – February 21, 2024 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences...
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
Designation Based on Pre-clinical Data and Initial Clinical Data from the Company’s MAvERIC-Pilot Phase II Study
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences company focused on the research...
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
Toronto, ON – November 1, 2023 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a clinical-stage life sciences...